Study design
PDAC
DISEASE PROGRESSION
Study I3Y‐MC‐JPCJ was an international, multicenter, adaptive, randomized, open‐label, Phase 2 study in patients with metastatic PDAC who had disease progression after 1 or 2 prior therapies. The study aimed to evaluate the safety and efficacy of abemaciclib monotherapy or in combination with targeted agents versus standard chemotherapy of physician's choice, using a 2‐stage design (Figure Dose selection for abemaciclib as monotherapy and in combination with LY3023414 or with galunisertib, as well as doses for LY3023414 and galunisertib were based on previously reported Phase 1 studies.